Abstract

IgG4-Related Disease (IgG4-RD) is a fibroinflammatory condition characterized by a typical histopathological pattern (dense lymphoplasmacytic infiltrate with prevalent IgG4+ plasma cells and storiform fibrosis), which may involve the kidney both directly (IgG4-related kidney disease, IgG4-RKD) or indirectly, as a consequence of post-renal ureteral obstruction due to retroperitoneal fibrosis (IgG4-RD RF). The most frequent presentation of IgG4-RKD is IgG4-related tubulointerstitial nephritis (TIN), but a glomerular disease can be present, in most of the cases a membranous nephropathy. Albeit steroid-responsive, in some cases renal manifestations may lead to progressive and permanent organ damage. In this review we describe four clinical cases representative of typical and less typical renal manifestations of IgG4-RD, emphasizing a potential, subclinical, early involvement of the kidney in the disease.

Highlights

  • IgG4-Related Disease (IgG4-RD) is a rare fibroinflammatory disorder that can affect almost any organ, characterized by lymphoplasmocytoid infiltrate, obliterative phlebitis, and storiform fibrosis often associated with eosinophilia and increased levels of IgG4 [1]

  • We report 4 cases of IgG4-RD with renal involvement that exemplify the different pattern of renal disease that can be observed in this disorder, outlining the clinical course and therapeutic approach

  • The case we describe in this report is of particular relevance, because renal histology shows a glomerulonephritis compatible with Associated Vasculitis (AAV), with rupture of Bowman capsulae and fibrinoid necrosis, together with a tubulointerstitial involvement and IgG4+plasmacells, more typical of IgG4-RD

Read more

Summary

INTRODUCTION

IgG4-RD is a rare fibroinflammatory disorder that can affect almost any organ, characterized by lymphoplasmocytoid infiltrate, obliterative phlebitis, and storiform fibrosis often associated with eosinophilia and increased levels of IgG4 [1]. Rituximab is an anti CD20 monoclonal treatment that demonstrates a dramatic efficacy in IgG4-RD, thanks to depletion of B cells and reduction of inflammatory infiltrate: treatment with Rituximab in the early stages of the disease can reverse fibrosis Even in this case, clinical remission may last 6–18 months. A 47 years old woman was evaluated in our outpatient clinics for AIP diagnosed 3 years before in another hospital (abdominal pain, hyperamilasemia; “Salt and pepper,” non-homogeneous pancreatic parenchyma at echography; serum IgG4 256 mg/dL) She had been treated with budesonide 9 mg/die and was under treatment with anti-IL-5 (Mepolizumab) for severe asthma. A renal biopsy was performed, showing mild thickening of glomerular basal membrane and focal mesangial expansion; minimal interstitial fibrosis and IgG4-negative lymphomonocytic infiltrate; minimal tubular atrophy (5% of tubuli) in the absence of vascular abnormalities. After surgical drainage of abdominal abscess, the patient’s conditions improved and no relapse of IgG4-RD in any localization was observed in follow up

DISCUSSION
Findings
CONCLUSIONS
DATA AVAILABILITY STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call